Strimvelis: Gene Therapy for Bubble Baby Disease

It has been one year since GlaxoSmithKline''s gene therapy Strimvelis for treating ADA- deficient Severe combined immunodeficiency (ADA-SCID) has been approved for sale in Europe. However, the cost of the treatment which amounts to 594,000 Euros has limited its sale. The National Institute for Health and Care Excellence (NICE) has in an unprecedented manner approved GSK''s pricey gene therapy, Strimvelis, as an option to treat the rare immune deficiency condition.
Email bookmark
Font : A-A+

Related Links